Please login to the form below
Mayzent
This page shows the latest Mayzent news and features for those working in and with pharma, biotech and healthcare.
Novartis wins FDA approval for relapsing MS drug Kesimpta
Kesimpta’s approval in relapsing MS builds on Novartis’ existing presence in the therapy area, which includes its active secondary progressive multiple sclerosis (SPMS) therapy Mayzent (siponimod).
Latest news
-
Novartis builds its case for novel MS treatment ofatumumab
The drug is an important product in Novartis’ growing MS franchise, which currently includes Mayzent (siponimod), a next-generation treatment approved for use in active secondary progressive multiple sclerosis (SPMS).
-
J&J aims for US approval of MS drug ponesimod
If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only
-
Biogen triumphs over Mylan’s Tecfidera patent challenge
language. Although the patent dispute is an overwhelming win, Biogen has been facing other challenges in the MS market from new treatments, including Novartis’ newly-approved Mayzent and Roche’s Ocrevus.
-
Cosentyx, Entresto drive topline growth for Novartis in Q4
Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and
-
Novartis gets EU approval for multiple sclerosis therapy Mayzent
The approvals are underpinned by data from a clinical trial that compared Mayzent to placebo. ... Novartis thinks the problem is a consequence of the novel nature of Mayzent.
More from news
Approximately 4 fully matching, plus 20 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Roche’s Ocrevus boasts positive long-term data in MS
- Roche’s Ocrevus boasts positive long-term data in MS
- Leadership change within Bedrock Group
- Trials resume for AZ/Oxford University COVID-19 vaccine
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
PMHub
claire@dovetailstrategies.com
About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
